LEU TechneLite® Generator Update

Ira Goldman
Senior Director, Global Strategic Supply and Government Relations
Kathy McFadden
Vice-President, Commercial – Nuclear Products

DOE Mo-99 Topical Meeting
September 25, 2018
Knoxville, TN

60+ Years of Innovation, Providing Leading/Best-in-Class Imaging Agents and Products



Schematic for illustrative purposes only. Please see Indications and full Prescribing Information on product specific pages of Lantheus.com.

Lantheus at-a-Glance

- Global leader in diagnostic medical imaging
- Develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care
- Diversified portfolio serving Echocardiography and Nuclear Medicine specialties
  - Lead products include *DEFINITY*®, *TechneLite*® and *Xenon*
  - Dynamic pipeline contains promising next-generation imaging agents
- Worldwide distribution partnerships covering EU, APAC, and LatAm regions
- Operations in U.S., Puerto Rico and Canada with headquarters in North Billerica, MA
- 2017 worldwide revenue: $331.4 million
- ~480 employees including the largest dedicated echocardiography sales force based in North America
- IPO in June 2015 (Ticker: LNTH)

TechneLite® Generator History

- **^{99m}Tc- generator developed in Brookhaven National Labs in 1958 and commercialized in the mid 1960s**
- **^{99m}Tc generator manufactured by LMI and predecessors since 1967**
  - New England Nuclear (NEN) introduced Tc-99m Generator based on Mo-99 produced by neutron capture (^{98}Mo (n,γ) ^{99}Mo)
  - NDA for generator based on Mo-99 from fission of U-235 (^{235}U (n,f) ^{99}Mo) approved in 1975
- **TechneLite®, terminally sterilized generator introduced in 1993**
- **TechneLite®, CMS compliant LEU sourced Mo-99 introduced in 2013**

1967-1974

1974-1993



1993

2013

Lantheus Mo-99 Supply Chain

Reactors & Processors



Support for Non-HEU U.S. Domestic Supply

- **Lantheus has supported U.S. Government efforts to establish domestic, non-HEU Mo-99 production**
  - Lantheus testimony, House Energy and Commerce Committee, 2009
  - Supported American Medical Isotope Production Act (AMIPA); passed in 2012, signed into law Jan. 1, 2013
  - CORAR engagement with Congress and DOE
  - Lantheus consistent participation in informal coalitions to promote additional U.S. cooperative funding and Q9969 $10 add-on payment
- **Lantheus has supported U.S. Government efforts to convert medical isotope production to LEU**
  - First generator manufacturer to qualify LEU-produced Mo-99 for use in TechneLite® generators (South Africa 2010; Australia 2011)
  - First to produce all LEU Mo-99 generator in January 2013 which met Center for Medicare Services criteria for $10 add-on payment

Upcoming LEU Mo-99 Supply Developments

- **ANM hot commissioning underway**
  - Validation runs planned for October
  - Commercial supply in 2Q2019
- **IRE LEU conversion progressing**
  - Validation runs expected in early 2019
  - Commercial supply in 2H2019

Future – LEU Supply from SHINE Medical

- **Lantheus and SHINE concluded supply agreement in Oct. 2014**
- **SHINE evaluated and supported by Department of Energy Cooperative Agreement program**
- **SHINE High Specific Activity Mo-99 will be compatible with Lantheus TechneLite® Tc-99m generator with no design changes**
- **Use of several accelerators and production lines means continuous production**
- **Alternative technology strengthens Lantheus Mo-99 supply diversification**
- **Lantheus also engages in regular discussions with other domestic projects, monitors progress**

Xe-133

- **Xe-133 used in U.S. for pulmonary imaging**
- **Lantheus longest continuous supplier of Xe-133 gas for pharmaceutical use**
- **Lantheus agreement with IRE in Jan. 2015 for supply of Xe-133 gas**
- **First commercial shipment June 30, 2016; IRE completely replaced NRU beginning in November 2016**
- **Additional diversification options being pursued**
- **LEU-based Xe-133 development advancing**

Conclusions

- **Lantheus has taken a leadership role in use of LEU Mo-99 in its TechneLite® generator supply chain**
- **LEU TechneLite® generators poised for significant increase in 2019**
- **LEU key to enhanced global nuclear security and creates foundation for more secure, reliable future supply of Mo-99**
- **Anticipate full conversion to LEU in 2019**
- **Lantheus and IRE have demonstrated reliable Xe-133 supply**

Thank you

Questions?